Edition:
United States

Sosei Group Corp (4565.T)

4565.T on Tokyo Stock Exchange

10,800JPY
2:00am EDT
Change (% chg)

¥40 (+0.37%)
Prev Close
¥10,760
Open
¥10,760
Day's High
¥10,930
Day's Low
¥10,600
Volume
309,000
Avg. Vol
679,046
52-wk High
¥26,180
52-wk Low
¥10,380

Latest Key Developments (Source: Significant Developments)

Sosei Group unit signs alliance for R & D of new small molecule therapeutic drug with DAIICHI SANKYO COMPANY LIMITED.
Monday, 13 Mar 2017 03:16am EDT 

Sosei Group Corp <4565.T>:Says its subsidiary Heptares signed an alliance for R & D of new small molecule therapeutic drug with DAIICHI SANKYO COMPANY LIMITED. on March 13.  Full Article

Sosei Group appoints Andrew Oakley as CFO
Thursday, 19 Jan 2017 01:51am EST 

Sosei Group Corp <4565.T>: Says it appoints Andrew Oakley as new CFO .Says effective date will be Feb. 1.  Full Article

Sosei Group says completion of Japanese Phase III clinical study of SO-1105 for oropharyngeal candidiasis
Monday, 29 Aug 2016 02:47am EDT 

Sosei Group <4565.T>: Says its Japanese subsidiary Sosei Co. Ltd. has completed the Japanese Phase III study of SO-1105 (miconazole 50 mg, muco-adhesive tablet) for the treatment of oropharyngeal candidiasis; meeting the primary endpoint as requested for submission . Says the study was an open-label, randomized, multi-site, parallel-group, comparative clinical study to investigate the efficacy and safety of SO-1105 in comparison with a commercialized formulation of miconazole in patients with oropharyngeal candidiasis in Japan .Says the cure rate after the completion of the targeted study medication period with SO-1105 was the same as the comparator in terms of the primary endpoint.  Full Article

Sosei Group says $10 million milestone payment from Astrazeneca to Heptares
Wednesday, 6 Jul 2016 02:00am EDT 

Sosei Group Corp <4565.T>:Says Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation, reported that it has been notified by its partner AstraZeneca that the first subject has been dosed with immuno-oncology candidate HTL1071 (AZD4635) in a Phase 1 clinical study, triggering a US$10 million payment from AstraZeneca.  Full Article

Sosei Group says appoints Peter Bains as CEO
Friday, 24 Jun 2016 06:14am EDT 

Sosei Group : Shinichi tamura, sosei founder and group chairman, president, ceo, appointed as representative executive officer and executive chairman .Sosei appoints Peter Bains as CEO.  Full Article

Sosei Group appoints Peter Bains as CEO
Friday, 24 Jun 2016 05:07am EDT 

Sosei Group Corp <4565.T>:Says the co appointed Peter Bains as CEO, effective June 24.  Full Article

Sosei Group's unit announces joint research with Kymab Limited
Monday, 18 Apr 2016 03:00am EDT 

Sosei Group Corp:Says its unit Heptares Therapeutics forms alliance with a bio-medical firm Kymab Limited, on joint research and commercialization of new antibody drugs in cancer immunotherapy therapy area.  Full Article

Sosei Group lowers consolidated full-year outlook for FY 2016
Wednesday, 6 Apr 2016 09:30pm EDT 

Sosei Group Corp:Says the company lowered the consolidated full-year outlook for revenue to 8,228 mln yen from 11,732 mln yen for the fiscal year ended March 31, 2016.Sees a decrease of operating profit forecast to 1,130 mln yen from 5,899 mln yen.Sees a decrease of ordinary profit forecast to a loss of 3,331 mln yen from 5,915 mln yen.Sees a decrease of net profit forecast to a loss of 3,444 mln yen from 6,047 mln yen.Sees a decrease of earnings per share to a loss of 225.06 yen from 439.02 yen.Comments the lower sales than expected, increased amortization expenses for intangible assets are the main reasons for the forecast.  Full Article

Sosei Group announces officer changes
Tuesday, 22 Mar 2016 02:30am EDT 

Sosei Group Corp:Says planned to appoint Peter Bains as president CEO to succeed Shinichi Tamura.Says planned to appoint Shinichi Tamura as chairman.Planned effective in June.  Full Article

Sosei Group announces new shares issuance
Monday, 14 Dec 2015 01:45am EST 

Sosei Group Corp:To issue 471,284 new shares through private placement at 8,537 yen per share, for 4,023,351,508 yen in total.Subscription date on Dec. 16 and payment date on Dec. 16.  Full Article

More From Around the Web

BRIEF-Sosei Group unit signs alliance for R & D of new small molecule therapeutic drug with DAIICHI SANKYO COMPANY LIMITED.

* Says its subsidiary Heptares signed an alliance for R & D of new small molecule therapeutic drug with DAIICHI SANKYO COMPANY LIMITED. on March 13